Selvita S.A. (SLV)
Warsaw Stock Exchange · Poland · prices in PLN · close of 19 Oct 2026
Key indicators
| Last close | PLN 18.90 |
|---|---|
| 52-week range | 18.90 – 49.40 |
| Return, 1 month / 3 months | −18.5% / −27.9% |
| Return, 1 year / 3 years | −48.2% / −69.6% |
| Trend | Below its 200-day average |
| RSI (14) | 27 |
| Volatility (1 year) | 41.6% |
| Worst drawdown (1 year) | -60.6% |
| Average daily value traded | 0.62M PLN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Selvita is a contract research organisation based in Krakow, Poland, that supports pharmaceutical and biotechnology companies in drug discovery and development. The company offers integrated services spanning medicinal chemistry, biology, pharmacology and preclinical studies, helping clients advance candidate compounds from early research toward clinical testing. Its customers are mainly life science firms that outsource laboratory work, and Selvita also develops its own early-stage drug programmes in areas such as oncology and central nervous system disorders.
The shares are listed on the Warsaw Stock Exchange in Poland under the code SLV, and the price on this page is in Polish zloty (PLN). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Selvita S.A. (SLV) trades on the Warsaw Stock Exchange in Poland. It last closed at PLN 18.90 on 19 October 2026.
Its price-based Market X-Ray is 26 out of 100 (a weak price profile), ranking 485 of 580 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 48.2% and over the last three months it fell 27.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Warsaw Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 4 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -42.1% | ||
| From 52-week high | -60.6% | ||
| Momentum | 7 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -27.9% | ||
| 6-month return | -46.0% | ||
| 12-month return, skipping the last month | -36.4% | ||
| Stability (higher is calmer) | 32 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -60.6% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 0.62M PLN | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −10.0% |
|---|---|
| 1 month | −18.5% |
| 3 months | −27.9% |
| 6 months | −46.0% |
| 1 year | −48.2% |
| 3 years | −69.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 24.80 / 32.66 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.96 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Warsaw Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.